MELANOMA STAGE III

This study tests whether combining two drugs—cyclophosphamide and pembrolizumab—can shrink tumors in people with advanced melanoma that no longer responds to standard immunotherapy. About 14 adults with stage III or IV melanoma will receive the combination. The goal is to see if …

This study tests a new treatment called [212Pb]VMT01, which delivers targeted radiation directly to melanoma cells. It is for people with advanced melanoma that has not responded to prior treatments. The study will see if this therapy is safe and effective when used alone or with…

This study tests whether giving immunotherapy before and after surgery helps people with advanced melanoma (stage III or IV). About 90 adults will receive treatment based on their tumor's unique markers. The goal is to see if this approach leads to a major or complete response in…

This study tests whether combining two drugs, binimetinib and imatinib, can shrink tumors in people with advanced KIT-mutant melanoma that cannot be surgically removed. About 25 participants with stage III or IV melanoma will receive the drug combination. The goal is to see how m…

This study looks at whether giving extra treatment after surgery can lower the chance of melanoma coming back in people with advanced stage III or IV melanoma that has a BRAF V600 mutation. About 50 adults will receive a combination of two drugs (encorafenib and binimetinib) befo…

This study is for people with advanced melanoma (stage III or IV that cannot be removed by surgery) whose cancer has stopped responding to standard immunotherapy drugs like nivolumab or pembrolizumab. The trial tests a new sequence of three drugs: high-dose interleukin-2 (IL2) pl…

This study looks at how beta-glucan, a natural fiber from yeast or mushrooms, affects the immune system in people with stage III or IV melanoma who are already taking the immunotherapy drug pembrolizumab. Researchers will measure changes in immune cells from blood samples. The go…

This study follows 40 people who received Miltenyi CAR T cell therapy at least one year ago. Researchers will track side effects, blood cell counts, growth, and overall health over time. The goal is to understand the long-term safety of these treatments.

This study looks at whether combining PET/CT scans with a special blood test (ctDNA) can help doctors predict which patients with advanced melanoma will respond to immunotherapy and who might have side effects. About 24 adults with stage III or IV melanoma will be followed for ab…